Company: MBIO
Filing Date: 2025-04-04
Form Type: POS AM
Source: 0001104659-25-032236
Chunk: 8

Company: MUSTANG BIO, INC.
Filing Date: 2025-04-04
Form: POS AM
Chunk 8
---

“assume,” “believe,” “contemplate,” “continue,” “could,” “design,”
“due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,”
“plan,” “positioned,” “potential,” “predict,” “seek,” “should,”
“target,” “will,” “would” and other similar expressions that are predictions of or indicate future
events and future trends, or the negative of these terms or other comparable terminology. In addition, statements that “we believe”
or similar statements reflect our beliefs and opinions on the relevant subject. All forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially from those expressed in, or implied by these, forward-looking statements
and therefore, you should not unduly rely on such statements, including, but not limited to:

| · | expected losses; |

| · | expectations for increases or decreases in expenses; |

| · | the substantial doubt expressed about our ability to continue as a going concern; |

| · | expectations for future capital requirements; |

| · | expectations for generating revenue or becoming profitable on a sustained basis; |

| · | expectations for the clinical and pre-clinical development, manufacturing, regulatory approval, and commercialization 
 of our pharmaceutical product candidates or any other products we may acquire or in-license;                          |

| · | use of clinical research centers and other contractors; |

| · | expectations for incurring capital expenditures to expand our research and development and manufacturing 
 capabilities;                                                                                            |

| · | expectations or ability to enter into marketing and other partnership agreements; |

| · | expectations or ability to enter into product acquisition and in-licensing transactions; |

| · | expectations or ability to build our own commercial infrastructure to manufacture, market and sell our 
 product candidates, if approved;                                                                       |

| · | expectations for the acceptance of our product candidates, if approved, by doctors, patients or payors; |

| · | ability to compete against other companies and research institutions; |

| · | ability to secure adequate protection for our intellectual property; |

| · | ability to attract and retain key personnel; |

| · | ability to obtain reimbursement for our products, if approved; |

| · | estimates of the sufficiency of our existing cash and cash equivalents and investments to finance our    
 operating requirements, including expectations regarding the value and liquidity of our investments; and |

| · | stock price and the volatility of the equity markets, including as